Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers.

Data is taken at the market close – at 4.10pm AEDT.

Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade.



Scroll or swipe to reveal table. Click headings to sort.

WordPress Tables Plugin

Atomo Diagnostics (ASX:AT1) had a jointly developed COVID-19 test given Emergency Use Authorisation by the FDA.

Hydrix (ASX:HYD) also got FDA approval for its medical device, namely the heart monitoring device AngelMed Guardian.

In resources, Indonesia focused gold play Nusantara Resources (ASX:NUS) got a takeover offer.

Cloud-based software as a service (SaaS) logistics company Yojee (ASX:YOJ) also rose after landing an expanded deal with an unnamed multinational customer, which will would result Yojee getting access to 18 additional markets in the Asia-Pacific where the customer operates.



WordPress Tables Plugin

Cyclopharm (ASX:CYC) meanwhile was sent back to the drawing board by the FDA.

The FDA advised that it could not approve Cyclopharm’s nuclear lung imaging agent Technegas in its present form and provided a list of items and recommendations for outstanding elements to be addressed within the next 12 months.

The ASX’s newest gold explorer Barton Gold (ASX:BGD) fell on its ASX debut.